Arvinas, Inc. announced new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial for vepdegestrant, presented at the 2025 European Society for Medical Oncology (ESMO) Congress. The data showed that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to fulvestrant in ESR1-mutated patients.
These PRO findings complement the previously reported clinical efficacy and safety data from VERITAC-2, further reinforcing vepdegestrant's potential as a treatment option for patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. The reduced risk of deterioration was statistically significant across several PRO domains, including overall health status, pain severity, and various functioning aspects.
Additionally, results from the TACTIVE-N Phase 2 clinical trial were presented, demonstrating that neoadjuvant vepdegestrant showed biological and clinical activity in treatment-naïve, predominantly ESR1 wild-type postmenopausal women with ER+/HER2- localized breast cancer. This expands the potential utility of vepdegestrant beyond the metastatic setting.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.